APA (7th ed.) Citation

Chen, H., Kuo, Y., Chen, C., Chang, C., Wang, S., Chien, Y., . . . Yu, C. (2024). Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy. The oncologist (Dayton, Ohio), 29(4), e498-e506. https://doi.org/10.1093/oncolo/oyad340

Chicago Style (17th ed.) Citation

Chen, Hsing-Wu, et al. "Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy." The Oncologist (Dayton, Ohio) 29, no. 4 (2024): e498-e506. https://doi.org/10.1093/oncolo/oyad340.

MLA (9th ed.) Citation

Chen, Hsing-Wu, et al. "Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy." The Oncologist (Dayton, Ohio), vol. 29, no. 4, 2024, pp. e498-e506, https://doi.org/10.1093/oncolo/oyad340.